Code of Conduct and Responsible Business

Our company is active in healthcare systems around the world. That’s why our senior leadership is accountable for ensuring we respect the highest standards of ethics and integrity, and conduct our business in a responsible, sustainable way.  
Paul Hudson (CEO) introduces Sanofi’s Code of Conduct

Our Code of Conduct

Every day at Sanofi, we chase the miracles of science to improve people’s lives. This means being exemplary in how we do business and unlock our innovation potential - because when it comes to building trust, the actions we take and decisions we make speak louder than words.
 
Our Code of Conduct is our constitution, supporting each of us to maximize opportunities while minimizing risks; to make bold and ethical decisions that activate our purpose; and to keep our patients and customers at the heart of all we do.

Speak Up

Sanofi is committed to conducting business with honesty and integrity and creating an inclusive environment where people feel empowered and safe to Speak Up.  We want to reassure you that you can raise concerns in good faith without fear of retaliation, even if those concerns turn out to be mistaken or unfounded.  If it doesn't feel right, follow your instincts and Speak Up.

Speak Up is Sanofi's confidential reporting channel hosted by Convercent and is not part of the Sanofi website or intranet.

We will listen.  We will look into it.  We will follow a transparent process.  We will have fair outcomes.

Ethics and Business integrity 

Sanofi operates in more than 100 countries around the world and is committed to respect the highest standards of ethics and integrity in its business conduct. Embedding ethical values into our day-to-day activities is essential to preserve the trust of patients and communities, to safeguard our image and reputation and to protect Sanofi employees. To sustain our commitment, we have implemented a robust governance. We have established and enforced clear rules in accordance with the legal framework in each country where we operate. A rigorous internal control framework is also implemented to prevent violations of internal rules.

Human Rights 

We employ more than 91,000 people in many countries and work with a large number of suppliers and subcontractors. This gives us a duty to respect the human rights of workers both in our own operations and in our supply chain.  

Patient safety always comes first 

We do everything we can to guarantee quality at each phase of a product’s life cycle. 

Promotional Practices

We constantly assess product quality and provide up-to-date information to healthcare professionals and patients.

Quality Management

We continually monitor and improve quality– systems, risk management, performance, and culture– globally and locally.

Pharmacovigilance

We collect data about all our products and collaborate with authorities all over the world to monitor their safety.

Information on Sodium Valproate (Depakine)

Ensuring the quality and safety of our products is our priority. Please find the latest update on sodium valproate.

Information on Dengvaxia®

Ensuring the quality and safety of our products is our priority. Please find the latest update on Dengvaxia.

Medical Ethics and Bioethics 

Our Bioethics Committee, chaired by our Chief Medical Officer, ensures we make progress through responsible practices in research and clinical development. It reviews bioethical standards and working practices in R&D for consistency and transparency, and determines relevant policy positions.

Sustainable Procurement 

Our centralized Procurement team acts on behalf of all Sanofi entities, following a policy based on economic, ethical, environmental, and social principles. We’re an active member of the Pharmaceutical Supply Chain Initiative, which aims to improve supplier practices through common standards, support, training, and audits. This helps us deliver on our commitments to society. 

Our transparency commitments

Interactions with HCPs

We disclose our interactions with HCPs and organizations, and medical and scientific associations, in 40 countries.

Scientific Exchange

We publish our findings in scientific and medical journals, and endorse the Principles of Responsible Sharing of Clinical Trial Data set by EFPIA and PhRMA.

Clinical studies and results

We make all ongoing clinical study protocols available, and publish our study results, both positive and negative

Animals in research and testing 

Our Integrated Research and Testing Strategy reflects our belief that the responsible use of animals in research and testing is essential and extends beyond regulatory requirements. Since 2013, we have reduced our use of animals in research and production by 45%.

Our policy documents and other relevant factsheets

Explore more

Manufacturing & Supply

Animals in research and production

Sodium valproate

Information on Dengvaxia®

Document Center